Skip to main content

A Path to Implement Precision Child Health Cardiovascular Medicine.

Publication ,  Journal Article
Touma, M; Reemtsen, B; Halnon, N; Alejos, J; Finn, JP; Nelson, SF; Wang, Y
Published in: Front Cardiovasc Med
2017

Congenital heart defects (CHDs) affect approximately 1% of live births and are a major source of childhood morbidity and mortality even in countries with advanced healthcare systems. Along with phenotypic heterogeneity, the underlying etiology of CHDs is multifactorial, involving genetic, epigenetic, and/or environmental contributors. Clear dissection of the underlying mechanism is a powerful step to establish individualized therapies. However, the majority of CHDs are yet to be clearly diagnosed for the underlying genetic and environmental factors, and even less with effective therapies. Although the survival rate for CHDs is steadily improving, there is still a significant unmet need for refining diagnostic precision and establishing targeted therapies to optimize life quality and to minimize future complications. In particular, proper identification of disease associated genetic variants in humans has been challenging, and this greatly impedes our ability to delineate gene-environment interactions that contribute to the pathogenesis of CHDs. Implementing a systematic multileveled approach can establish a continuum from phenotypic characterization in the clinic to molecular dissection using combined next-generation sequencing platforms and validation studies in suitable models at the bench. Key elements necessary to advance the field are: first, proper delineation of the phenotypic spectrum of CHDs; second, defining the molecular genotype/phenotype by combining whole-exome sequencing and transcriptome analysis; third, integration of phenotypic, genotypic, and molecular datasets to identify molecular network contributing to CHDs; fourth, generation of relevant disease models and multileveled experimental investigations. In order to achieve all these goals, access to high-quality biological specimens from well-defined patient cohorts is a crucial step. Therefore, establishing a CHD BioCore is an essential infrastructure and a critical step on the path toward precision child health cardiovascular medicine.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Front Cardiovasc Med

DOI

ISSN

2297-055X

Publication Date

2017

Volume

4

Start / End Page

36

Location

Switzerland

Related Subject Headings

  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Touma, M., Reemtsen, B., Halnon, N., Alejos, J., Finn, J. P., Nelson, S. F., & Wang, Y. (2017). A Path to Implement Precision Child Health Cardiovascular Medicine. Front Cardiovasc Med, 4, 36. https://doi.org/10.3389/fcvm.2017.00036
Touma, Marlin, Brian Reemtsen, Nancy Halnon, Juan Alejos, J Paul Finn, Stanley F. Nelson, and Yibin Wang. “A Path to Implement Precision Child Health Cardiovascular Medicine.Front Cardiovasc Med 4 (2017): 36. https://doi.org/10.3389/fcvm.2017.00036.
Touma M, Reemtsen B, Halnon N, Alejos J, Finn JP, Nelson SF, et al. A Path to Implement Precision Child Health Cardiovascular Medicine. Front Cardiovasc Med. 2017;4:36.
Touma, Marlin, et al. “A Path to Implement Precision Child Health Cardiovascular Medicine.Front Cardiovasc Med, vol. 4, 2017, p. 36. Pubmed, doi:10.3389/fcvm.2017.00036.
Touma M, Reemtsen B, Halnon N, Alejos J, Finn JP, Nelson SF, Wang Y. A Path to Implement Precision Child Health Cardiovascular Medicine. Front Cardiovasc Med. 2017;4:36.

Published In

Front Cardiovasc Med

DOI

ISSN

2297-055X

Publication Date

2017

Volume

4

Start / End Page

36

Location

Switzerland

Related Subject Headings

  • 3201 Cardiovascular medicine and haematology